Antares Pharma Inc (NASDAQ:ATRS) has received a consensus recommendation of “Buy” from the eight brokerages that are currently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, five have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $4.83.

Several analysts recently issued reports on the company. Cowen assumed coverage on Antares Pharma in a report on Monday, February 25th. They set an “outperform” rating and a $1.99 target price on the stock. BidaskClub upgraded Antares Pharma from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. TheStreet upgraded Antares Pharma from a “d” rating to a “c” rating in a report on Friday, March 1st. Finally, Raymond James upped their target price on Antares Pharma from $5.25 to $5.65 and gave the stock a “strong-buy” rating in a report on Monday, March 4th.

Shares of Antares Pharma stock opened at $2.72 on Friday. The stock has a market capitalization of $436.65 million, a PE ratio of -68.00 and a beta of 1.11. Antares Pharma has a one year low of $2.16 and a one year high of $3.96. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.20 and a current ratio of 2.62.

Antares Pharma (NASDAQ:ATRS) last issued its quarterly earnings results on Thursday, February 28th. The specialty pharmaceutical company reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.06. The company had revenue of $18.82 million for the quarter, compared to analyst estimates of $18.36 million. Antares Pharma had a negative return on equity of 22.42% and a negative net margin of 10.25%. Analysts predict that Antares Pharma will post -0.02 earnings per share for the current fiscal year.

In related news, Director Jacques Gonella sold 200,000 shares of the company’s stock in a transaction dated Tuesday, February 26th. The stock was sold at an average price of $3.65, for a total transaction of $730,000.00. Following the sale, the director now owns 9,385,848 shares in the company, valued at $34,258,345.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Leonard S. Jacob sold 92,078 shares of the company’s stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $3.00, for a total value of $276,234.00. Following the sale, the director now owns 301,970 shares in the company, valued at approximately $905,910. The disclosure for this sale can be found here. Corporate insiders own 12.20% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. increased its position in Antares Pharma by 112.2% during the third quarter. JPMorgan Chase & Co. now owns 941,117 shares of the specialty pharmaceutical company’s stock worth $3,162,000 after buying an additional 497,523 shares during the last quarter. BlackRock Inc. increased its position in Antares Pharma by 1.3% during the third quarter. BlackRock Inc. now owns 9,929,257 shares of the specialty pharmaceutical company’s stock worth $33,362,000 after buying an additional 123,932 shares during the last quarter. Allianz Asset Management GmbH increased its position in Antares Pharma by 17.4% during the third quarter. Allianz Asset Management GmbH now owns 891,286 shares of the specialty pharmaceutical company’s stock worth $2,995,000 after buying an additional 132,113 shares during the last quarter. MetLife Investment Advisors LLC increased its position in Antares Pharma by 53.3% during the third quarter. MetLife Investment Advisors LLC now owns 109,970 shares of the specialty pharmaceutical company’s stock worth $369,000 after buying an additional 38,239 shares during the last quarter. Finally, Morgan Stanley increased its position in Antares Pharma by 17.3% during the third quarter. Morgan Stanley now owns 760,870 shares of the specialty pharmaceutical company’s stock worth $2,557,000 after buying an additional 112,221 shares during the last quarter. Institutional investors and hedge funds own 41.41% of the company’s stock.

Antares Pharma Company Profile

Antares Pharma, Inc focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.

Recommended Story: The Discount Rate – What You Need to Know

Analyst Recommendations for Antares Pharma (NASDAQ:ATRS)

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.